A new class in mood disorders?

A new class in mood disorders

It was a great pleasure to attend a keynote address by Professor Jules Angst: one of the key figures in the field of bipolar I disorder research and, this reporter suspects, one of the few delegates at IRPB 2015 famous enough to warrant their own Wikipedia page.

Still pushing the boundaries of research

 

Now in his 89th year, Professor Angst continued to enhance the understanding of bipolar I disorder with a challenging, thorough and very positively received talk on the proposed concept of “unipolar mania” as a “necessary diagnostic concept”.

 

DSM-5 and then some

 

Professor Angst was part of the early committee who helped design the DSM-5 diagnostic criteria. He firmly believes that bipolar I disorders exist as a broad spectrum of mania, with depression as a core feature. However, he believes there is a small but significant class of patients who lie beyond the current DSM-5 spectrum – those who display so-called “unipolar mania” He presented several from around the world in support of this theory.

 

A class apart

 

“Unipolar mania” is relatively uncommon, with two separate epidemiological studies of community subjects reporting an incidence of less than 2%.1,2 Patients with “unipolar mania” present with different clinical characteristics to typical bipolar I disorder patients, with an earlier onset, fewer episodes, lower comorbidities, better long-term adjustment and more psychotic features, among other differentiating factors.3

Citing an (astonishing) 50-year epidemiology study, he showed evidence that this putative patient class were significantly longer lived than bipolar I patients: in a cohort of 403 patients followed between 1959 and 2009, mortality in the “unipolar mania” group was 76.7% vs. 89.2% in bipolar-I patients.4 This difference, the Professor postulated, was a result of the lower frequency of suicide and different patterns of substance abuse among this patient class.4

 

Keeping a future focus

 

Professor Angst concluded his talk by, in general, speaking positively about the DSM-5 scale but warning against complacency. He encouraged delegates to continue their own research into the diagnosis and treatment of patients with mood disorders – especially into the little-researched field covered in today’s address.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. Beesdo K, et al. 2009; Bipolar Disord 11(6): 637–649.
  2. Merikangas KR, et al. 2012; Arch Gen Psychiatry 69(9): 943–951.
  3. Angst J, Grobler C. Eur Arch Psychiatry Clin Neurosci 2015 Jan 29. DOI 10.1007/s00406-015-0677-1
  4. Angst J, et al., 2013. Eur Arch Psychiatry Clin Neurosci 263(5): 425–434.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country